Date: 2012-11-12
Type of information: Production agreement
Compound: multiple DARPin® products
Company: Molecular Partners (Switzerland) Boehringer Ingelheim (Germany)
Therapeutic area:
Type agreement: manufacturing
production
Action mechanism: DARPins® are a new generation of target-binding proteins which can be isolated from large libraries. They combine the high specificity, selectivity and safety of monoclonal antibodies with many advantages of small molecules, including high stability and low-cost production and adding the ability of combining multiple specificities. Also, DARPins® show very high potencies and pharmacokinetic (PK) profiles tailored to the demand of the application, ranging from minutes to weeks. DARPins® can be effortlessly combined into multispecific drug candidates without compromising biophysical and development characteristics. This rapid and robust generation of multispecific DARPins® allows new combinatorial approaches in exploring target biology. Molecular Partners is focusing on DARPin® drugs in inflammation, oncology, ophthalmology and other disease areas. The most advanced DARPin® (MP0112) is in phase IIb clinical development and has been partnered with Allergan.
Disease:
Details: Molecular Partners and Boehringer Ingelheim’s biopharmaceutical contract manufacturing business have entered into a strategic manufacturing collaboration. Under the terms of the agreement, Boehringer Ingelheim will be responsible for the generation of the E. coli production strains and the manufacture of tox and clinical stage material for multiple DARPin® products supplying Molecular Partners’ proprietary DARPin® pipeline.
Financial terms:
Latest news:
